Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus

Table 1

Characteristic of all studies included in the meta-analysis.

Study	Country	Study type	Mean age (years); E : C	No. of patients; E : C	Mean BMI (kg/m^2); E : C	Experimental group	Experimental dose	Control group	Control dose	Outcome measures
Ji et al., 2017	China	RCT	64.6/64.2	60/60	25/23	AL+AT	10 mg/d/6 m + 10 mg/d/6 m	AL	10 mg/d/6 m	A, G
Su et al., 2019	China	RCT	64/64	40/40	NP	AL+AT	10 mg/d/6 m + 10 mg/d/6 m	AL	10 mg/d/6 m	A, D, F, H
Duan et al., 2019	China	RCT	67.58/68.39	50/50	NP	AL+AT	10 mg/d/6 m + 10 mg/d/6 m	AL	10 mg/d/6 m	A, G, H
Fu et al., 2020	China	RCT	65.7/65.9	59/59	24.95/25.03	AL+AT	10 mg/d/6 m + 10 mg/d/6 m	AL	10 mg/d/6 m	A, B, C, D, E, F, G, H
Zou et al., 2021	China	RCT	62.45/62.48	40/40	23.55/23.51	AL+AT	10 mg/d/6 m + 10 mg/d/6 m	AL	10 mg/d/6 m	B, C, D, E, G, H
Li et al., 2017	China	RCT	65.5/66.5	90/90	24.58/25.5	AL+AT	70 mg/w/6 m + 10 mg/d/6 m	AL	70 mg/w/6 m	A, G, H
Wang et al., 2017	China	RCT	68.7/67.2	75/75	NP	AL+AT	70 mg/w/6 m + 10 mg/d/6 m	AL	70 mg/w/6 m	G, H
Wang et al., 2019	China	RCT	64.2/63.3	20/20	NP	AL+AT	70 mg/w/6 m + 10 mg/d/6 m	AL	70 mg/w/6 m	A, C, D, E, F, H
Yang et al., 2019	China	RCT	66.27/66.43	35/35	23.04/23.25	AL+AT	70 mg/w/6 m + 10 mg/d/6 m	AL	70 mg/w/6 m	A, C, E, F, H
Hu et al., 2020	China	RCT	58.23/57.89	100/100	NP	AL+AT	70 mg/w/6 m + 10 mg/d/6 m	AL	70 mg/w/6 m	B, H
Hou et al., 2018	China	RCT	64.5/62.5	40/40	NP	AL+AT	70 mg/w/6 m + 10 mg/d/12 m	AL	70 mg/w/6 m	A, H
Li X et al., 2019	China	RCT	65.09/65.43	50/50	NP	AL+AT	10 mg/w/6 m + 10 mg/d/12 m	AL	10 mg/d/6 m	A, B
Li Y et al., 2019	China	RCT	68.4/67.5	29/29	NP	AL+AT	70 mg/w/6 m + 10 mg/d/12 m	AL	70 mg/w/6 m	A, H
Feng et al., 2019	China	RCT	58.93/61.9	50/50	NP	AL+AT	70 mg/w/6 m + 10 mg/d/12 m	AL	70 mg/w/6 m	H

E: experimental group; C: control group; RCT: randomized controlled trial; BMI: body mass index; AL: alendronate; AT: atorvastatin; d: day; w: week; m: month; NP: not provided. Outcome measure: A: BMD (femoral neck, femoral trochanter, forearm, lumbar spine); B: VAS; C: OPG; D: BGP; E: BAP; F: blood P and Ca; G: total effective rate; H: adverse events.